Issue

Vol. 66 No. 3: Issue 3

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Expression and clinical diagnostic value of miR-383 in patients with severe preeclampsia

https://doi.org/10.14715/cmb/2020.66.3.14
Ting Li
Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Nanhua University, Hengyang 421001, China
Bing Zhou
Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Nanhua University, Hengyang 421001, China
Yijing He
Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Nanhua University, Hengyang 421001, China
Jue Liu
Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Nanhua University, Hengyang 421001, China
Yun Li
Department of brain function and neuroelectricity science,Affiliated Nanhua Hospital,University of South China,  Hengyang 421002,China

Corresponding Author(s) : Yun Li

yunli231@mail.ru

Cellular and Molecular Biology, Vol. 66 No. 3: Issue 3

Abstract

This study aimed to investigate the expression and clinical diagnostic value of miR-383 in patients with severe preeclampsia. Thirty patients with severe preeclampsia from July 2017 to December 2018 were selected as a research group, twenty healthy pregnant women undergoing physical examination at the same period were selected as a control group, and miR-383 and miR-16 in placenta tissue of the two groups were detected by qRT-PCR. ROC curve was drawn to evaluate the predictive value of diagnostic efficiency, Spearman test was used for correlation analysis, and Logistic univariate and multivariate analysis was performed on the risk factors related to the metastasis of severe preeclampsia. The miR-383 expression in the research group was significantly lower than that in the control group (P< 0.001), while the miR-16 expression in the research group was significantly higher than that in the control group (P< 0.001). The miR-383 and miR-16 expression levels were tied to TNM staging and metastasis (P< 0.001). The sensitivity, specificity and AUC of miR-383 single diagnosis were 75.00%, 83.33% and 0.847 respectively, and those of miR-16 single diagnosis were 65.00%, 63.33% and 0.728 respectively. The relative expression of miR-383 in placenta tissue was negatively correlated with APACHE II score of severe preeclampsia (r = -0.4129, P= 0.0233), but the relative expression of miR-16 in placenta tissue was positively correlated with APACHE II score of severe preeclampsia (r = 0.9833, P< 0.001). Blood pressure, miR-383, miR-16 at the admission of pregnant women were independent risk factors for severe preeclampsia. miR-383 and miR-16 might participate in the process of occurrence, development and metastasis of severe preeclampsia, and could be used as potential biomarkers of placental tissue for its diagnosis and disease assessment of metastasis.

Keywords

miR-383 Severe preeclampsia Clinical diagnosis miR-16 APACHE â…¡ score.
Li, T., Zhou, B., He, Y., Liu, J., & Li, Y. (2020). Expression and clinical diagnostic value of miR-383 in patients with severe preeclampsia. Cellular and Molecular Biology, 66(3), 92–100. https://doi.org/10.14715/cmb/2020.66.3.14
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Duffy J, Thompson T, Hinton L, Salinas M, McManus RJ, Ziebland S; International Collaboration to Harmonise Outcomes in Pre-eclampsia (iHOPE) Qualitative Research Group: What outcomes should researchers select, collect and report in pre"eclampsia research? A qualitative study exploring the views of women with lived experience of pre"eclampsia. BJOG 126: 637-646, 2019.
  2. Ukah UV, Magee L, Payne B, et al: 320. Pregnancy characteristics, management and outcomes according to different definitions of pre-eclampsia and other hypertensive disorders of pregnancy. Pregnancy Hypertens 13: S125, 2018.
  3. Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, Singh M, Greco E, Wright A, Maclagan K, et al: Comparison of diagnostic accuracy of early screening for pre"eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol 51: 743-750, 2018.
  4. Phipps EA, Thadhani R, Benzing T and Karumanchi SA: Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology, 2019: 1.
  5. Phipps E A, Thadhani R, Benzing T, et al. Author Correction: Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 15: 386-386, 2019.
  6. Ayansina D, Black C, Hall SJ, Marks A, Millar C, Prescott GJ, Wilde K and Bhattacharya S: Long term effects of gestational hypertension and pre-eclampsia on kidney function: Record linkage study. Pregnancy Hypertens 6: 344-349, 2016.
  7. Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, et al: Implementation of the sFlt"1/PlGF ratio for prediction and diagnosis of pre"eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 45: 241-246, 2015.
  8. Mohseni Z, Spaanderman MEA, Oben J, Calore M, Derksen E, Al-Nasiry S, de Windt LJ and Ghossein-Doha: Cardiac remodeling and pre"eclampsia: an overview of microRNA expression patterns. Ultrasound Obstet Gynecol 52: 310-317, 2018.
  9. Schmiedel JM, Klemm SL, Zheng Y, Sahay A, Blüthgen N, Marks DS and van Oudenaarden A: MicroRNA control of protein expression noise. Science 348: 128-132, 2015.
  10. Hill JM and Lukiw WJ: MicroRNA (miRNA)-mediated pathogenetic signaling in Alzheimer's disease (AD). Neurochem Res 41: 96-100, 2016.
  11. Murphy MSQ, Tayade C and Smith GN: Maternal circulating microRNAs and pre-eclampsia: challenges for diagnostic potential. Mol Diagn Ther 21: 23-30, 2017.
  12. Skalis G, Katsi V, Miliou A, Georgiopoulos G, Papazachou O, Vamvakou G, Nihoyannopoulos P, Tousoulis D and Makris T: MicroRNAs in Preeclampsia. MicroRNA 8: 28-35, 2019.
  13. Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, Poon WS and Ng HK: MiR"383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol 23: 413-425, 2013.
  14. Garrido-Gomez T, Ona K, Kapidzic M, Gormley M, Simón C, Genbacev O and Fisher SJ: Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. Development 144: 767-777, 2017.
  15. Lam JK, Chow MY, Zhang Y and Leung SW: siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids 4: e252, 2015.
  16. Munaut C, Tebache L, Blacher S, Noí«l A, Nisolle M and Chantraine F: Dysregulated circulating miRNAs in preeclampsia. Biomed Rep 5: 686-692, 2016.
  17. Jiang L, Long A, Tan L, Hong M, Wu J, Cai L and Li Q: Elevated microRNA-520g in pre-eclampsia inhibits migration and invasion of trophoblasts. Placenta 51: 70-75, 2017.
  18. Rupaimoole R, Calin GA, Lopez-Berestein G and Sood AK: miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov 6: 235-246, 2016.
  19. Chen L, Guan H, Gu C, Cao Y, Shao J and Wang F: miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL. Tumour Biol 37: 2497-2507, 2016.
  20. Fang Z, He L, Jia H, Huang Q, Chen D and Zhang Z: The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer. Iran J Basic Med Sci 20: 187, 2017.
  21. Pei L, Meng S, Yu W, Wang Q, Song F and Ma L: Inhibition of microRNA-383 ameliorates injury after focal cerebral ischemia via targeting PPARγ. Cell Physiol Biochem 39: 1339-1346, 2016.
  22. Wei GJ, Zheng KW, An G, Shi ZW, Wang KF, Guan Y, Wang YS, Li PF and Dong DM: Comprehensive Effects of Suppression of MicroRNA-383 in Human Bone-Marrow-Derived Mesenchymal Stem Cells on Treating Spinal Cord Injury. Cell Physiol Biochem 47: 129-139, 2018.
  23. Wang Y, Fan H, Zhao G, Liu D, Du L, Wang Z, Hu Y and Hou Y: miR"16 inhibits the proliferation and angiogenesis"regulating potential of mesenchymal stem cells in severe pre"eclampsia. FEBS J 279: 4510-4524, 2012.
  24. Mencí­a Castaño I, Curtin CM and Duffy GP and O'Brien FJ: Harnessing an inhibitory role of miR-16 in osteogenesis by human mesenchymal stem cells for advanced scaffold-based bone tissue engineering. Tissue Eng Part A 25: 24-33, 2019.
  25. Li Q, Pan Z, Wang X, Gao Z, Ren C and Yang W: miR-125b-1-3p inhibits trophoblast cell invasion by targeting sphingosine-1-phosphate receptor 1 in preeclampsia. Biochem Biophys Res Commun 453: 57-63, 2014.
  26. Awamleh Z, Gloor GB and Han VKM: Placental microRNAs in pregnancies with early onset intrauterine growth restriction and preeclampsia: potential impact on gene expression and pathophysiology. BMC Med Genomics 12: 91, 2019.
  27. Alrahmani L and Willrich MAV: The complement alternative pathway and preeclampsia. Curr Hypertens Rep 20: 40, 2018.
  28. Aziz S and Shahid R: Reversible Blindness in Severe Preeclampsia. Journal of the Society of Obstetrics and Gynaecologists of Pakistan 7: 110-111, 2017.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 804 Download : 475